EP1176141A4 — HETEROCYCLIC COMPOUNDS HAVING RECEPTOR ACTIVATION EFFECT $ g (a) 4 $ g (b) 2 OF NICOTINIC ACETYLCHOLINE
Assigned to Asubio Pharma Co Ltd · Expires 2002-08-14 · 24y expired
What this patent protects
Heterocyclic compounds showing an affinity for nicotinic acetylcholine α4β2 receptor and activating the same to thereby exert a preventive or therapeutic effect on brain diseases. Namely, nicotinic acetlycholine α4β2 receptor activators comprising, as the active ingredient, compo…
USPTO Abstract
Heterocyclic compounds showing an affinity for nicotinic acetylcholine α4β2 receptor and activating the same to thereby exert a preventive or therapeutic effect on brain diseases. Namely, nicotinic acetlycholine α4β2 receptor activators comprising, as the active ingredient, compounds represented by general formula (I) or pharmacologically acceptable salts thereof and drugs containing the same: wherein A represents optionally substituted aryl or an optionally subsituted heterocycle; X represents oxygen, sulfur, carbon or nitrogen; dotted lines represent each the presence or absence of a bond; n is an integer of 1 or 2; and Y represents alkylene, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.